News
ENSC
0.5200
-5.66%
-0.0312
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 1d ago
Weekly Report: what happened at ENSC last week (0406-0410)?
Weekly Report · 1d ago
Ensysce Biosciences files to sell 20.34M shares of common stock for holders
TipRanks · 5d ago
Ensysce Biosciences Secures $2 Million Private Financing
TipRanks · 6d ago
Ensysce Biosciences secures second financing from 2025 agreement
TipRanks · 04/07 12:52
Ensysce Biosciences Closes Second Convertible Preferred Stock Financing Of $2M Under Prior Commitment In November 2025 Of Up To $20M Funding Available Over 24 Months
Benzinga · 04/07 12:06
Ensysce Biosciences closes USD 2 million convertible preferred stock private placement
Reuters · 04/07 12:06
Weekly Report: what happened at ENSC last week (0330-0403)?
Weekly Report · 04/06 10:42
Ensysce Biosciences Announces Board Member Curtis Rosebraugh Resignation
TipRanks · 04/03 20:27
Ensysce Biosciences director Curtis Rosebraugh resigns from board
Reuters · 04/03 20:15
Watching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $16.45 Price Valuation, Says "Earnings Release Show Positive
Momentum"
Benzinga · 03/31 15:06
Ensysce Biosciences Q4 EPS $(0.75) Misses $(0.70) Estimate, Sales $1.882M Beat $500.000K Estimate
Benzinga · 03/30 21:24
Ensysce Biosciences Q4 net loss narrows to $2.8 mln
Reuters · 03/30 21:02
Ensysce Biosciences GAAP EPS of -$0.75 beats by $0.51
Seeking Alpha · 03/30 20:53
ENSYSCE BIOSCIENCES Q4 NET INCOME USD -2.8 MILLION
Reuters · 03/30 20:50
Weekly Report: what happened at ENSC last week (0323-0327)?
Weekly Report · 03/30 10:42
Ensysce Biosciences director Lee Rauch resigns from board amid retention package dispute
Reuters · 03/30 10:02
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 03/24 12:05
Ensysce Biosciences Corrects Series B Preferred Stock Designation
TipRanks · 03/23 12:30
Weekly Report: what happened at ENSC last week (0316-0320)?
Weekly Report · 03/23 10:37
More
Webull provides a variety of real-time ENSC stock news. You can receive the latest news about Ensysce Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About ENSC
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.